ImmunoTherapyNews.net

Cancer immunotherapy

Xagena Mappa
Medical Meeting
XagenaNewsletter
Reumabase.it

Search results for "Solid tumors"

Immune-suppressing molecules such as PD-L1 can be co-opted by cancer cells to suppress the natural immune response to cancer. Upregulation of PD-L1 and inhibition of antitumor T-cell activation is obs ...


Pembrolizumab ( Keytruda ) is a potent, highly selective humanized monoclonal antibody against PD-1 designed to block interaction with PD-L1 and PD-L2 and remove the inhibition of T-cell activation ag ...


Immune-suppressing molecules such as PD-L1 can be co-opted by cancer cells to suppress the natural immune response to cancer. Upregulation of PD-L1 and inhibition of antitumor T-cell activation is obs ...


Programmed cell death ligand-1 ( PD-L1 ) is widely expressed on antigen presenting cells ( APC ) and other immune cells. PD-L1 binds two important regulatory receptors on T-cells: programmed cell deat ...


A subset of patients treated with immune checkpoint inhibitors experience an accelerated tumor growth rate ( TGR ) in comparison with pretreatment kinetics; this is known as hyperprogression. A stud ...